FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1812338265> ?p ?o ?g. }

• W1812338265 endingPage "500" @default.
• W1812338265 startingPage "490" @default.
• W1812338265 abstract "This study examined the effects of the CYP3A/P-glycoprotein inducer, rifampicin, on the pharmacokinetics of dabigatran following oral administration of the prodrug, dabigatran etexilate.This was an open-label, fixed-sequence, four-period study in healthy volunteers. Subjects received a single dose of dabigatran etexilate 150 mg on day 1, rifampicin 600 mg once daily on days 2-8, and single doses of dabigatran etexilate on days 9, 16 and 23.Twenty-four subjects were treated, of whom 22 received all treatments. Relative to the reference (single dose of dabigatran etexilate alone; treatment A), administration of dabigatran etexilate following 7 days of rifampicin (treatment B) decreased the geometric mean (gMean) area under the concentration-time curve (AUC(0-∞)) and maximal plasma concentration (C(max)) of total dabigatran by 67 and 65.5%, respectively. The time to peak and the terminal half-life were not affected. The gMean ratio for the primary comparison (treatment B vs. treatment A) was 33.0% (90% confidence interval 26.5, 41.2%) for AUC(0-∞) and 34.5% (90% confidence interval 26.9, 44.1%) for C(max), indicating a significant effect on total dabigatran exposure (total pharmacologically active dabigatran represents the sum of nonconjugated dabigatran and dabigatran glucuronide). After a 7 day (treatment C) or 14 day washout (treatment D), the AUC(0-∞) and C(max) of dabigatran were reduced by 18 and 20%, and by 15 and 20%, respectively, compared with treatment A, which was considered not clinically relevant. The overall safety profile of all treatments was good.Administration of rifampicin for 7 days resulted in a significant reduction in the bioavailability of dabigatran, which returned almost to baseline after 7 days washout." @default.
• W1812338265 created "2016-06-24" @default.
• W1812338265 creator A5004615988 @default.
• W1812338265 creator A5023011657 @default.
• W1812338265 creator A5028737342 @default.
• W1812338265 creator A5064405454 @default.
• W1812338265 creator A5070867379 @default.
• W1812338265 creator A5081398468 @default.
• W1812338265 creator A5082973437 @default.
• W1812338265 date "2012-08-06" @default.
• W1812338265 modified "2023-09-27" @default.
• W1812338265 title "Decrease in the oral bioavailability of dabigatran etexilate after co-medication with rifampicin" @default.
• W1812338265 cites W107839322 @default.
• W1812338265 cites W1860620208 @default.
• W1812338265 cites W1969867250 @default.
• W1812338265 cites W1982128407 @default.
• W1812338265 cites W1988747841 @default.
• W1812338265 cites W2000438765 @default.
• W1812338265 cites W2015273497 @default.
• W1812338265 cites W2022545732 @default.
• W1812338265 cites W2030021013 @default.
• W1812338265 cites W2035193897 @default.
• W1812338265 cites W2062946016 @default.
• W1812338265 cites W2065847221 @default.
• W1812338265 cites W2071381562 @default.
• W1812338265 cites W2089840820 @default.
• W1812338265 cites W2094792978 @default.
• W1812338265 cites W2114089215 @default.
• W1812338265 cites W2115348966 @default.
• W1812338265 cites W2119622751 @default.
• W1812338265 cites W2124882231 @default.
• W1812338265 cites W2132083523 @default.
• W1812338265 cites W2136489990 @default.
• W1812338265 cites W2203036336 @default.
• W1812338265 doi "https://doi.org/10.1111/j.1365-2125.2012.04218.x" @default.
• W1812338265 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3477350" @default.
• W1812338265 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/22348256" @default.
• W1812338265 hasPublicationYear "2012" @default.
• W1812338265 type Work @default.
• W1812338265 sameAs 1812338265 @default.
• W1812338265 citedByCount "106" @default.
• W1812338265 countsByYear W18123382652012 @default.
• W1812338265 countsByYear W18123382652013 @default.
• W1812338265 countsByYear W18123382652014 @default.
• W1812338265 countsByYear W18123382652015 @default.
• W1812338265 countsByYear W18123382652016 @default.
• W1812338265 countsByYear W18123382652017 @default.
• W1812338265 countsByYear W18123382652018 @default.
• W1812338265 countsByYear W18123382652019 @default.
• W1812338265 countsByYear W18123382652020 @default.
• W1812338265 countsByYear W18123382652021 @default.
• W1812338265 countsByYear W18123382652022 @default.
• W1812338265 countsByYear W18123382652023 @default.
• W1812338265 crossrefType "journal-article" @default.
• W1812338265 hasAuthorship W1812338265A5004615988 @default.
• W1812338265 hasAuthorship W1812338265A5023011657 @default.
• W1812338265 hasAuthorship W1812338265A5028737342 @default.
• W1812338265 hasAuthorship W1812338265A5064405454 @default.
• W1812338265 hasAuthorship W1812338265A5070867379 @default.
• W1812338265 hasAuthorship W1812338265A5081398468 @default.
• W1812338265 hasAuthorship W1812338265A5082973437 @default.
• W1812338265 hasBestOaLocation W18123382652 @default.
• W1812338265 hasConcept C112705442 @default.
• W1812338265 hasConcept C126322002 @default.
• W1812338265 hasConcept C181389837 @default.
• W1812338265 hasConcept C2776301958 @default.
• W1812338265 hasConcept C2778810321 @default.
• W1812338265 hasConcept C2779161974 @default.
• W1812338265 hasConcept C42219234 @default.
• W1812338265 hasConcept C42404028 @default.
• W1812338265 hasConcept C44249647 @default.
• W1812338265 hasConcept C71924100 @default.
• W1812338265 hasConcept C76318530 @default.
• W1812338265 hasConcept C98274493 @default.
• W1812338265 hasConceptScore W1812338265C112705442 @default.
• W1812338265 hasConceptScore W1812338265C126322002 @default.
• W1812338265 hasConceptScore W1812338265C181389837 @default.
• W1812338265 hasConceptScore W1812338265C2776301958 @default.
• W1812338265 hasConceptScore W1812338265C2778810321 @default.
• W1812338265 hasConceptScore W1812338265C2779161974 @default.
• W1812338265 hasConceptScore W1812338265C42219234 @default.
• W1812338265 hasConceptScore W1812338265C42404028 @default.
• W1812338265 hasConceptScore W1812338265C44249647 @default.
• W1812338265 hasConceptScore W1812338265C71924100 @default.
• W1812338265 hasConceptScore W1812338265C76318530 @default.
• W1812338265 hasConceptScore W1812338265C98274493 @default.
• W1812338265 hasIssue "3" @default.
• W1812338265 hasLocation W18123382651 @default.
• W1812338265 hasLocation W18123382652 @default.
• W1812338265 hasLocation W18123382653 @default.
• W1812338265 hasLocation W18123382654 @default.
• W1812338265 hasOpenAccess W1812338265 @default.
• W1812338265 hasPrimaryLocation W18123382651 @default.
• W1812338265 hasRelatedWork W2017999632 @default.
• W1812338265 hasRelatedWork W2048588916 @default.
• W1812338265 hasRelatedWork W2169439801 @default.
• W1812338265 hasRelatedWork W2319431964 @default.
• W1812338265 hasRelatedWork W2354680669 @default.

• next